MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers.

MiR-106b25 has been researched in several cancers. The aim of this study was to test miR-106b25 expressions in 40 operative specimens and 20 pre-operative plasma samples of GC patients and explore the correlations between these miRNAs and some related clinical pathological factors. Compared with corresponding adjacent non-tumorous tissues, the expression of miR-106b25 cluster increased significantly in gastric cancer tissues from 40 samples, with a median relative expression of 2.41(miR-106b), 2.83(miR-93) and 2.71(miR-25). The expression of miRNA-106b25 cluster in tumor tissues was significantly correlated with tumor size, borrmann type, depth of tumor invasion (T), lymph node metastases (N), distant metastasis (M) and TNM stage (P<0.05). The expressive level of miRNA-106b25 cluster was also statistically significant higher than healthy volunteers in plasma, with a median of 2.51(miR-106b), 2.32(miR-93) and 2.10(miR-25). The expression of miR-106b25 cluster in plasma was significantly correlated with tumor size, borrmann type and TNM stage (P<0.05) in GC patients. What's more, the three components of miR-106b25 cluster expressed consistently at a high level both in specimens and plasma. Considering the relationship between three miRNAs and some clinical pathological factors (TNM stage), it was implied that miR-106b25 could be the next potential tumor biomarker for diagnosis and predictive prognosis for gastric cancer patients.